| Literature DB >> 9667970 |
P S Dragovich1, S E Webber, R E Babine, S A Fuhrman, A K Patick, D A Matthews, C A Lee, S H Reich, T J Prins, J T Marakovits, E S Littlefield, R Zhou, J Tikhe, C E Ford, M B Wallace, J W Meador, R A Ferre, E L Brown, S L Binford, J E Harr, D M DeLisle, S T Worland.
Abstract
The structure-based design, chemical synthesis, and biological evaluation of peptide-derived human rhinovirus (HRV) 3C protease (3CP) inhibitors are described. These compounds incorporate various Michael acceptor moieties and are shown to irreversibly bind to HRV serotype 14 3CP with inhibition activities (kobs/[I]) ranging from 100 to 600 000 M-1 s-1. These inhibitors are also shown to exhibit antiviral activity when tested against HRV-14-infected H1-HeLa cells with EC50's approaching 0.50 microM. Extensive structure-activity relationships developed by Michael acceptor alteration are reported along with the evaluation of several compounds against HRV serotypes other than 14. A 2.0 A crystal structure of a peptide-derived inhibitor complexed with HRV-2 3CP is also detailed.Entities:
Mesh：
Substances：
Year: 1998 PMID： 9667970 DOI： 10.1021/jm980068d
Source DB: PubMed Journal: J Med Chem ISSN： 0022-2623 Impact factor: 7.446